Compare Fubotv Inc (FUBO) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs ResMed Inc. — how do they compare? Fubotv Inc trades at $9.28 (market cap $1.06B), while ResMed Inc. trades at $224.94 (market cap $32.61B). The key difference: ResMed Inc. is far larger — about 30.8× Fubotv Inc's market cap, and ResMed Inc. pays a 1.17% dividend while Fubotv Inc pays none. Which is the better fit depends on your goals.
| FUBO | RMD | |
|---|---|---|
Market Cap | $1.06B | $32.61B |
Sector | Technology | Health |
52-Week High | $54.72 | $293.73 |
52-Week Low | $8.09 | $182.82 |
Enterprise Value | $1.23B | $31.97B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO trades at $9.46, up 1.07% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q3 2026 revenue of $1.48 billion (Business Wire, 2026-08-05) and raised its full-year adjusted EBITDA target to $90–$100 million. Valuation ratios appear attractive with a P/S of 0.19 and P/B of 0.36, while recent earnings showed mixed results with two beats and one miss in the last four quarters.
The outlook is cautiously optimistic with analyst consensus pointing to significant upside to a $15.33 price target. Key opportunities include subscriber growth from live sports and advertising improvements, but risks persist from negative cash flows and high debt levels. Execution under new CEO Alisa Bowen and partnerships with Disney and NBCUniversal are critical for achieving profitability targets.
ResMed (RMD) trades at $225.17, up 2.33% today, reflecting strong recent earnings beats and robust fundamentals. The stock exhibits a bullish technical trend, supported by positive moving averages, with key resistance near $227. Financially, the company shows impressive growth, with Q4 2026 revenue reaching a record $1.5 billion (Reuters, 2026-08-07) and a net income margin of 26.94%. Recent strategic moves include the divestiture of the MatrixCare business to sharpen focus on core sleep and respiratory care markets.
The outlook for RMD is positive, driven by consistent earnings outperformance and strategic portfolio optimization. However, investors face risks from weaker-than-expected fiscal 2027 revenue guidance and competitive pressures in the medtech sector. The consensus price target of $235.00 (MarketBeat, 2026-08-09) suggests modest upside potential, supported by a majority analyst hold rating amid solid long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
